Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oteo

Showing results (571-580 of 658) with videos related to

Pageof 66
Sort By:
Lancet (London, England)|July 10, 2020
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological studyMarina Pollán, Beatriz Pérez-Gómez, Roberto Pastor-Barriuso, et al.
The Journal of Antimicrobial Chemotherapy|October 5, 2012
Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in SpainJesús Oteo, Juan Manuel Hernández, Mateu Espasa, et al.
Clinical Drug Investigation|May 21, 2011
Clinical utility of maravirocJorge Parra, Joaquín Portilla, Federico Pulido, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2025
Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinationsLucía Sánchez-Peña, Salud Rodríguez-Pallares, Pablo Aja-Macaya, et al.
Antimicrobial Agents and Chemotherapy|October 9, 2024
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing EnterobacteralesTania Blanco-Martín, Inmaculada López-Hernández, Belén Aracil, et al.
Journal of Clinical Periodontology|March 21, 2021
Genome-wide association study of stage III/IV grade C periodontitis (former aggressive periodontitis) in a Spanish populationAlicia de Coo, Raquel Cruz, Inés Quintela, et al.
Npj Imaging|February 10, 2026
A single-step radiolabeling strategy for PET, SPECT, and therapeutic radionuclides using nanoparticles as a universal chelatorAitor Herraiz, Andrea Rodríguez-San-Pedro, Marta Casquero-Veiga, et al.
Infection|May 4, 2024
Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in SpainElena Salamanca-Rivera, Zaira R Palacios-Baena, Javier E Cañada, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2015
Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenemJesús Oteo, Adriana Ortega, Rosa Bartolomé, et al.
BMJ (Clinical Research Ed.)|November 28, 2020
Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological studyRoberto Pastor-Barriuso, Beatriz Pérez-Gómez, Miguel A Hernán, et al.
Pageof 66

Showing results (571-580 of 658) with videos related to

Sort By:
Pageof 66
Lancet (London, England)|July 10, 2020
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological studyMarina Pollán, Beatriz Pérez-Gómez, Roberto Pastor-Barriuso, et al.
The Journal of Antimicrobial Chemotherapy|October 5, 2012
Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in SpainJesús Oteo, Juan Manuel Hernández, Mateu Espasa, et al.
Clinical Drug Investigation|May 21, 2011
Clinical utility of maravirocJorge Parra, Joaquín Portilla, Federico Pulido, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2025
Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinationsLucía Sánchez-Peña, Salud Rodríguez-Pallares, Pablo Aja-Macaya, et al.
Antimicrobial Agents and Chemotherapy|October 9, 2024
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing EnterobacteralesTania Blanco-Martín, Inmaculada López-Hernández, Belén Aracil, et al.
Journal of Clinical Periodontology|March 21, 2021
Genome-wide association study of stage III/IV grade C periodontitis (former aggressive periodontitis) in a Spanish populationAlicia de Coo, Raquel Cruz, Inés Quintela, et al.
Npj Imaging|February 10, 2026
A single-step radiolabeling strategy for PET, SPECT, and therapeutic radionuclides using nanoparticles as a universal chelatorAitor Herraiz, Andrea Rodríguez-San-Pedro, Marta Casquero-Veiga, et al.
Infection|May 4, 2024
Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in SpainElena Salamanca-Rivera, Zaira R Palacios-Baena, Javier E Cañada, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2015
Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenemJesús Oteo, Adriana Ortega, Rosa Bartolomé, et al.
BMJ (Clinical Research Ed.)|November 28, 2020
Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological studyRoberto Pastor-Barriuso, Beatriz Pérez-Gómez, Miguel A Hernán, et al.
Pageof 66